A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)
Not yet recruitingCTIS2024-519787-40-00
AstraZeneca ABEsophageal Cancer Expressing Claudin18.2, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Target: 126Updated: 2026-06-17